

# Psychometric properties of the original Inflammatory Bowel Disease Questionnaire, a Spanish version

Ángela Vidal<sup>a</sup>, Esther Gómez-Gil<sup>b</sup>, Miquel Sans<sup>c</sup>, Maria J. Portella<sup>d</sup>, Manel Salamero<sup>a</sup>, Josep M. Piqué<sup>c</sup> y Julián Panés<sup>c</sup>

<sup>a</sup>Department of Clinical Psychology. Hospital Clínic de Barcelona. Institut Investigacions Biomèdiques August Pi i Sunyer. Barcelona. Spain.

<sup>b</sup>Department of Psychiatry. Hospital Clínic de Barcelona. Institut Investigacions Biomèdiques August Pi i Sunyer. Barcelona. Spain.

<sup>c</sup>Department of Gastroenterology. Hospital Clínic de Barcelona. Institut Investigacions Biomèdiques August Pi i Sunyer. Barcelona. Spain.

<sup>d</sup>Research Institute. Department of Psychiatry. Hospital de la Santa Creu i Sant Pau. Universitat Autònoma de Barcelona. Spain.

## ABSTRACT

**BACKGROUND:** The Inflammatory Bowel Disease Questionnaire (IBDQ) was developed by Guyatt et al. (1989) and it is the most widely used health-related quality of life instrument for patients with Crohn's disease (CD) and ulcerative colitis (UC). The aim of this study was to assess the psychometric properties of a Spanish version of the original IBDQ by examining the instrument's underlying factor structure, the internal and external validity, and the internal consistency reliability

**MATERIAL AND METHOD:** One hundred and forty seven patients (76 CD, 71 UC) completed the Spanish version of the IBDQ, the Hospital Anxiety and Depression Scale (HADS) and the Temperament and Character Inventory (TCI). Clinical activity was assessed by the CDAI and the Truelove-Witts index.

**RESULTS:** The confirmatory factor analysis of the IBDQ failed to reproduce the original four-factor structure proposed by Guyatt et al. We found that the Spanish version of the IBDQ consists also of four underlying factors, but the content of each factor and the items included were slightly different. Psychometric testing of the IBDQ revealed that the questionnaire has an acceptable internal and external validity, and a high internal reliability.

**CONCLUSION:** Although confirmatory factor analyses failed to reproduce the original psychometric structure of IBDQ, it seems that the Spanish version of this instrument proved to be valid and reliable for assessing health related quality of life in inflammatory bowel disease patients.

## PROPIEDADES PSICOMÉTRICAS DEL CUESTIONARIO DE LA ENFERMEDAD INFLAMATORIA INTESTINAL: UNA VERSIÓN ESPAÑOLA

**FUNDAMENTO:** El Cuestionario de la Enfermedad Inflamatoria Intestinal (Inflammatory Bowel Disease Questionnaire [IBDQ]), desarrollado por Guyatt et al en 1989, es el instrumento de calidad de vida más ampliamente usado en pacientes con la enfermedad de Crohn (EC) y colitis ulcerosa (CU). El objetivo de este estudio fue evaluar las propiedades psicométricas de la versión española del original IBDQ mediante el examen de la estructura factorial del instrumento, su validez externa e interna, y su fiabilidad.

**MATERIAL Y MÉTODO:** Ciento cuarenta y siete pacientes (76 con EC y 71 con CU) cumplieron la versión española del IBDQ, la Escala Hospitalaria de Ansiedad y Depresión (HAD) y el Inventario de Temperamento y Carácter (TCI). La actividad clínica fue evaluada mediante el CDAI y el índice Truelove-Witts.

**RESULTADOS:** El análisis factorial confirmatorio de la versión española del IBDQ no reprodujo la original estructura de 4 factores propuesta por Guyatt et al. Si bien se hallaron también 4 factores, el contenido de cada factor y los ítems incluidos en cada uno de los factores era ligeramente distinto. El estudio psicométrico confirmó que el instrumento posee una validez interna y externa aceptable, y una alta fiabilidad.

**CONCLUSIÓN:** Aunque el análisis confirmatorio no reprodujo la original estructura del IBDQ, los resultados sugieren que la versión española es un instrumento válido y fiable para evaluar la calidad de vida de los pacientes con enfermedad inflamatoria intestinal.

Correspondence: A. Vidal.  
Psychology Department. Hospital Clínic.  
Villarroel, 170. 08036 Barcelona. Spain.  
E-mail: anvidal@clinic.ub.es

Recibido el 9-11-2006; aceptado para su publicación el 22-12-2006.

## INTRODUCTION

Crohn's disease (CD) and ulcerative colitis (UC) are chronic diseases that have significant physical, social, and

psychological repercussions<sup>1</sup>. Traditional clinical approach, focused on disease activity assessment, does not embody many difficulties patients experience due to their disease<sup>2</sup>. Therefore, a more comprehensive clinical evaluation must also include a tool to assess the individual's health-related quality of life. Such an approach may result into a better understanding of the patient's global situation and should contribute to better patient care.

The Inflammatory Bowel Disease Questionnaire (IBDQ) is the most widely used health-related quality of life instrument for patients with IBD. It was developed in 1989 by Guyatt and co-workers<sup>3</sup> in Canada. The aim of the IBDQ was to provide clinicians with a reliable, valid and a disease-specific questionnaire for identifying and quantifying the subjective health status for patients with IBD. Up till then a variety of generic questionnaires that were standard measures of health status were available<sup>4,5</sup>, but these measures may not focus adequately on the specific problems of IBD patients. The IBDQ has been translated and validated into several languages such as Dutch, UK-English, Korean, Swedish, Greek, Norwegian, Chinese, German, Portuguese, Japanese<sup>5-15</sup>. These versions have confirmed the soundness of the psychometric properties of IBDQ previously reported by the Canadian group<sup>3</sup>. There exists a validated Spanish version of the IBDQ<sup>16</sup>. These authors translated the modified version of the IBDQ of Love et al<sup>17</sup> and determined its validity, reliability and responsiveness. However, few studies have used the 36-item version by Love et al, whereas the 32-item original version by Guyatt et al<sup>3</sup> is the most used in studies and also in clinical settings.

Therefore, the aim of this study was to assess the psychometric properties of a Spanish version of the 32-item IBDQ, in order to provide a comparable version of this questionnaire for future gastroenterological studies. Exploratory and confirmatory factor analyses were used to examine the instrument's underlying factor structure. Therefore, the study aimed at investigating whether this version of the IBDQ is valid and reliable for UC and CD patients.

## METHODS

### Patients

One hundred and eighty-six IBD patients were invited to take part in the study. Patients were recruited through the IBD Unit of Hospital Clinic of Barcelona, Spain. All patients had been previously diagnosed as CD or UC on the basis of Lennard-Jones criteria<sup>18</sup>. Inclusion criteria established that patients were suffering a relapse or were in clinical remission but had had at least one exacerbation in the last 24 months. UC patients who had undergone a colectomy were excluded from the study. Patients were given a set of questionnaires, asked to fill them out at home and mail them in the next two weeks in the pre-addressed, postage-paid envelopes provided.

### Questionnaires

#### *The Inflammatory Bowel Disease Questionnaire (IBDQ)*

The IBDQ to be validated in this study is a translation of the 32-item original questionnaire that evaluates four dimensions: bowel symptoms

(e.g. loose stools, abdominal pain), systemic symptoms (e.g. fatigue, altered sleep patterns), emotional functioning (e.g. anger, irritability, depression), and social functioning (e.g. work attendance, need to cancel events). Responses are graded on a 7-point Likert scale (7 = not a problem; 1 = a very severe problem). The dimensional scores are the sum of the scores of the items included in each dimension. The sum score is the summation of the individual scores and giving a possible range of 32 to 224. Higher scores mean better quality of life.

#### *Hospital Anxiety and Depression Scale (HADS)*

The HADS<sup>19</sup> is a 14-item scale that evaluates anxiety and depression in medical patients. The total score is obtained by summing the ratings on the 14 items. The Spanish version of the HADS was translated by Herrero et al<sup>20</sup>. This instrument is used in several studies and also for validation of other instruments.

#### *Harm Avoidity (HA), a subscale of Temperament and Character Inventory (TCI)*

The TCI<sup>21</sup> is an instrument used for the dimensional study of the temperament and character components of personality. It is divided into 7 independent dimensions. Briefly, one dimension is HA, which reflects a tendency to be shy, careful, passive, insecure, worried in anticipation of possible danger. The Spanish version of the TCI was validated by Gutiérrez et al<sup>22</sup> and it is a reliable and valid instrument.

#### *Assessment of Disease Activity*

The disease activity of patients with CD was assessed by the Crohn's Disease Activity Index (CDAI). It is a disease-specific index that has demonstrated acceptable reliability and validity. CDAI scores less than 150 indicate clinical remission, while higher scores indicate active disease<sup>23</sup>. Patients with UC were assessed by the Truelove-Witts Index<sup>24</sup>. This scale has been widely used in research and clinical care because it is easy to use and is believed to give an accurate measure of the physician's assessment of activity. Scores less than eight indicate clinical remission, while a relapse is defined by a total score on the Truelove-Witts Index of at least 8 points.

## Statistical analysis

Descriptive data on frequency, percentage, means and standard deviations were used for the demographic and clinical characteristics. The IBDQ was evaluated regarding internal and external validity and internal consistency reliability.

### *Internal validity*

The aim of the internal validation of the Spanish version of IBDQ was to test the structure of the questionnaire and to ascertain if the use of a sum score and the 4-dimension scores could be confirmed.

– Confirmatory factor analyses were performed using R v 2.2.1<sup>25</sup>. We evaluated the fit of our data to the original four-factor structure, using the maximum likelihood estimation method. An exploratory factor analyses was carried out in the questionnaire using a principal-component method, followed with varimax rotation and Kaiser normalization. A scree plot was performed for determining the number of underlying factors with eigen-values above unity.

– To assess if an item measured the same area of health as the dimension it was supposed to belong, the following strategy was adopted: for the Item Convergent Validity, the correlation between an item and its dimension should be higher than 0.40. Likewise, for the Item Discriminant Validity the correlation should be at least 0.1 better to its own dimension than to any of other dimensions.

– To investigate if items measure one or several areas of health (correlation between scales), correlation between the four dimensions were performed. If correlation were below than 0.70 the dimensions would measure different areas of health.

### *External validity*

The concurrent and divergent validity and discriminating power were checked to test the external validity of the Spanish version of IBDQ.

– The concurrent validity was analyzed by correlating the IBDQ dimensions with the HADS and activity indexes. We tested the following hypotheses: *a*) The emotional function was hypothesized to have a high correlation with the HADS, and *b*) the bowel symptoms subscale was hypothesized to have a high correlation with the CDAI or the Truelove-Witts Index.

Validity was considered to have been confirmed when the scales measuring related concepts had a large correlation ( $r > 0.50$ ), and when these correlations were greater than those measuring different concepts.

– To assess its divergent validity, the total score of the IBDQ was correlated with the score of the Harm Avoidance scale of the TCI. We hypothesized to have a small correlation ( $r$  between 0.10 to 0.29).

– To investigate the power of the IBDQ to discriminate patients with exacerbation from those in remission (discriminating power), they were divided into two groups according to their activity index. Data were analysed using the Mann-Whitney U test for independent samples. The accepted level of statistical significance was  $p < 0.01$ .

**Reliability**

The internal consistency reliability was calculated with Cronbach’s alpha coefficient (McNemar method was used for correlation coefficient adjust) for the whole questionnaire and also for each dimension. The minimum acceptable value for alpha was 0.70.

**Ethics**

The protocol was approved by the ethical Committee of Research Ethics of Hospital Clínic. Each participant gave written informed consent before participation.

**RESULTS**

Out of 186 outpatients with CD and UC asked to participate and accepted. Of these, 39 cases did not send the questionnaire set before 15 days. Thus, the study comprised 147 patients, 76 (51.7%) with CD and 71 (48.3%) with UC. Demographic and disease-related factors are summarized in table I.

**Internal validity**

*Factor structure of the Spanish IBDQ*

The confirmatory factor analysis failed to reproduce the original 4-factor structure proposed by Guyatt et al. The model had a significant Chi<sup>2</sup> (Model Chisquare = 1522.4;  $p < 0.001$ ), a Goodness-of-fit index (GFI) of 0.59, and a root-mean-square error of approximation (RMSEA) of

0.12. Considering criteria by Hu and Bentler<sup>26</sup> (that is to say, Chi<sup>2</sup> have to be non-significant, adequate fit indices are GFI of 0.90 or greater and RMSEA 0.06 or lower) our results indicate a poor fit.

A principal component analysis was performed with a varimax rotation and Kaiser normalization. Table II displays the factor loadings greater than 0.40 from the factor analysis of 32 IBDQ items. An eigen-value greater than 1.0 as the criterion for cut-off resulted in six factors being extracted from the entire pool of items. However, the scree plot showed a flattening of the curve on factors 4, 5 and 6. The three analyses were performed, and the 4-factor analysis was accepted as the best one. They explained 60.8% of the variance. Factor loading and principal components analyses are given in table II.

*Factor I: emotional function*

According to the factor analysis, 10 of the items had their highest loading on this factor. Eight of these came from the emotional function dimension of the originally IBDQ, and the remaining two from the systemic symptoms subscale. Questions 6 and 27 have a similar factor loading on Factor I and Factor II and III respectively. Owing to their contents, we decided to include them to Factor I. This Factor explained 17.9% of the variance.

*Factor II: social function*

There are 6 questions with their highest loading on Factor II. Five items came from the social function subscale of the originally IBDQ, and one belonged to the emotional function subscale. This Factor explained 15.9% of the variance.

*Factor III: bowel movement*

Eight questions had their highest loading on Factor III, six of which came from the bowel symptoms dimension of the originally IBDQ. Question 11 has similar high factor loading on Factor II and Factor III, but given its content, it has been included in Factor III. This Factor explained 14.6% of the variance.

*Factor IV: bowel pain and discomfort*

There were seven items with their highest loading on Factor IV. Four items belonged to the bowel function subscale, two items belonged to the systemic symptom subscale, and one item to the emotional function subscale. Item 9 had also a high factor loading on Factor III, but given its high loading on Factor IV and its content, we included it in this last factor. Factor IV explained 12.4% of the variance.

The item «sleeping disturbance» from the systemic symptom dimension, did not load onto any of these four factors. This might be a case for excluding this item from the Spanish version of the IBDQ.

TABLE I. Demographic and disease-related factors of the study sample (n = 147)

	Number (frequency [%] or mean [range])
Gender	
Female patients	76 (51.7)
Male patients	71 (48.3)
Age	37.2 (18-75)
Type of disease	
Crohn’s disease	76 (51.7)
Ulcerative colitis	71 (48.3)
Duration of IBD, months	72.2 (1-336)
Disease activity	
Remission	111 (75.5)
Relapse	36 (24.5)

TABLE II. Exploratory factor analyses of the IBDQ by a principal-component method with Varimax rotation and Kaiser normalization. Only factor loadings greater than 0.40 are listed

Items	Factor I	Factor II	Factor III	Factor IV
<b>Bowel symptoms</b>				
1. Stool frequency			0.69	
2. Loose stools			0.60	
9. Abdominal cramps			(0.40)	0.72
13. Abdominal pain				0.74
17. Passing gas			0.54	
20. Abdominal bloating				0.66
22. Rectal bleeding			0.69	
24. Feeling of defecation need			0.67	
26. Soiling			0.68	
20. Sick stomach				0.64
<b>Systemic symptoms</b>				
2. Tired and worn out	0.54			
6. Energy	0.44	(0.48)		
10. Generally unwell				0.62
14. Sleeping disturbance*				
18. Weight problems				0.41
<b>Emotional function</b>				
3. Frustrated/impatient	0.80			
7. Worried about surgery		0.65		
11. Fear of not finding a toilet		(0.52)	0.58	
15. Depressed/discouraged	0.78			
19. Disease-related worries				0.45
21. Relaxed/free of tension	0.74			
23. Embarrassed with bowel movement			0.70	
25. Tearful or upset	0.72			
27. Angry owing to bowel symptoms	0.47		(0.57)	
30. Irritable	0.83			
31. Lack of understanding	0.75			
32. Satisfaction personal life	0.76			
<b>Social function</b>				
4. Work/School		0.80		
8. Cancel social engagement		0.71		
12. Leisure or sports activities		0.79		
16. Avoid events without toilets		0.81		
28. Sexual activity		0.69		
%Variance of all items explained by each factor	17.87	15.94	14.59	12.45

Numbers in parentheses are factor loadings greater than 0.40, but where the item has been included in another factor.

\*This item did not load in to any of the four factors.

### Item convergent and item discriminant validity

Convergent and discriminant validity for the four IBDQ original dimensions are presented in table III.

The correlation between the items and their hypothetical scales was > 0.4 for all items apart from the item «worried about surgery» that correlated < 0.40 with all dimensions. The percentage of items in each dimension that correlated at least 0.1 higher with their own dimension than with other dimension was 90% for bowel symptoms, 80% for systemic symptoms, 66% for emotional function, and 100% for social function.

### Correlation between scales

Inter-dimensional correlations for the four dimensions are presented in table IV. It can be observed that only the correlation between emotional function and systemic symptoms was higher than 0.70.

### External validity

#### Concurrent validity

Table IV illustrates the correlation between the four dimensions and clinical variables (disease activity and HADS).

As expected, we found a correlation higher than 0.5 between the Truelove-Witts Index and the CDAI with the bowel function subscale. However, the correlation between the CDAI and some unrelated domains (systemic symptoms and social function) were higher than expected.

The correlation between the HADS and emotional function was high. However, the correlation between the HADS and systemic symptoms was higher than we expected. This could be explained by the high inter-dimensional correlation between emotional function and systemic symptoms subscales (r = 0.74).

TABLE III. **Convergent and discriminant item-validity of the IBDQ**

Item function	Bowel symptoms	Systemic symptoms	Emotional function	Social function
<b>Bowel symptoms</b>				
1. Stool frequency	0.71			
2. Loose stools	0.75			
9. Abdominal cramps	0.81			
13. Abdominal pain	0.78			
17. Passing gas	0.66			
20. Abdominal bloating	0.62			
22. Rectal bleeding	0.54			
24. Feeling of defecation need	0.72			
26. Soiling	0.57			(0.49)
20. Sick stomach	0.62			
<b>Systemic symptoms</b>				
2. Tired and worn out		0.82		
6. Energy		0.69		
10. Generally unwell	(0.75)	0.72	(0.62)	(0.69)
14. Sleeping disturbance		0.69		
18. Weight problems		0.56		
<b>Emotional function</b>				
3. Frustrated/impatient			0.81	
7. Worried about surgery	(0.38)	(0.29)	0.38	(0.40)
11. Fear of not finding a toilet	(0.60)	(0.49)	0.58	(0.63)
15. Depressed/discouraged			0.84	
19. Disease-related worries			0.67	
21. Relaxed/free of tension			0.76	
23. Embarrassed with bowel movement	(0.66)	(0.54)	0.58	(0.52)
25. Tearful or upset			0.74	
27. Angry owing to bowel symptoms	(0.65)		0.73	(0.67)
30. Irritable			0.77	
31. Lack of understanding			0.67	
32. Satisfaction personal life			0.68	
<b>Social function</b>				
4. Work/School				0.69
8. Cancel social engagement				0.74
12. Leisure or sports activities				0.91
16. Avoid events without toilets				0.75
28. Sexual activity				0.77

The item is supposed to correlate satisfactory ( $r > 0.40$ ) with its own dimension, and at least 0.1 better with its own dimension than with any other dimension than its own. Correlations are presented within parenthesis if the item did not correlate at least 0.1 lower with the other dimensions than with its own dimension.

TABLE IV. **Inter-dimensional correlation between the four IBDQ dimensions. Correlations between the four IBDQ dimensions and the activity index and the HADS. Correlation between the sum score of IBDQ and Harm avoidance of TCI. Cronbach's alpha of the scale and four dimensions**

Parameter	Bowel symptoms	Systemic symptoms	Emotional function	Social function	Total sum of IBDQ	Cronbach's alpha
IBDQ total						0.95
Bowel symptoms						0.88
Systemic symptoms	0.61					0.74
Emotional function	0.64	0.74				0.91
Social function	0.67	0.64	0.66			0.89
<b>Activity Index</b>						
CDAI	-0.51	-0.54	-0.39	-0.59		
Truelove-Witts Index	-0.60	-0.25	-0.31	-0.28		
HADS	-0.26	-0.51	-0.69	-0.34		
Harm Avoidance (TCI)					-0.33	

*Divergent validity*

The correlation between the total score of the IBDQ and the Harm Avoidance scale of the TCI was higher than we hypothesized ( $r = -0.33$ ). However, divergent validity could be considered acceptable.

*Discriminating power*

The results showed that the IBDQ had a very high power ( $p < 0.001$ ) to discriminate exacerbated patients and remitted patients in both UC and CD (data not shown).

*Reliability*

The Cronbach's alpha value for IBDQ sum score was 0.95, for the bowel symptoms subscale was 0.87, for the systemic symptoms subscale was 0.74, for emotional function subscale was 0.91, and for social function subscale was 0.88. All values surmounted the criterion for acceptable internal reliability.

**DISCUSSION**

The aim of the present study was to evaluate the psychometric properties of a Spanish version of the IBDQ. It is

the first time that a Spanish version of the 32-item IBDQ has been validated. This study has shown that this version of IBDQ is a valid and reliable measure of health-related quality of life for Spanish IBD patients.

In relation to the internal structure of the IBDQ, there are some concerns. The confirmatory factor analysis failed to reproduce the original four-factor structure proposed by Guyatt et al<sup>3</sup>. These results are in agreement with the three previous studies that have included a factor analysis for the IBDQ validation<sup>7,9,11</sup>, which also have found other factor structures that the one proposed by Guyatt et al. Two of them<sup>7,11</sup> found five underlying factors, and the other one<sup>9</sup> found a structure of six factors. One explanation might be that in the development of the original IBDQ, items were arranged into four dimensions on the basis of clinical reasoning, and no factor analyses were checked. Moreover, an exploratory analysis to determine both the number of factors and the items in each factor in the Spanish version of IBDQ could be of paramount importance. The factor structure found in this study respect the four factors of the original IBDQ, but the content of each factor and their items are slightly different. Although the results does not resemble the original structure, given that the factor structure found has been confirmed by exploratory factor analysis, the Spanish version of the IBDQ can be considered a useful instrument for gastroenterologists. The convergent item validity was excellent and the discriminant item validity was acceptable. The inter-dimensional correlations revealed moderate correlations between the four dimensions, thus the IBDQ seem to measure several areas of health. Therefore, the IBDQ could be more understandable as a group of different dimensions than as a total sum score for the whole questionnaire, although a global score of the IBDQ is also interpretable.

In terms of external validity, the Spanish version of IBDQ showed acceptable concurrent and divergent validity. These results might suggest that the IBDQ does not assess a personality trait on the tendency to be neurotic but different quality of life aspects. Concerning the discriminating power, results suggested that the Spanish IBDQ was able to discriminate successfully between patients with different clinical disease activity, which endorse more validity to the instrument.

Finally, in our study, the internal consistency reliability was very high for both the whole scale and for each dimension. These results suggest that the Spanish version of IBDQ shows an excellent internal consistency. The coefficient found in this study is alike to that obtained in other validated versions of the IBDQ, such as 0.95 in the Swedish version<sup>9</sup>, 0.92 in the Portuguese version<sup>14</sup>, and 0.93 in the Dutch version<sup>6</sup>.

In conclusion, the Spanish IBDQ has been shown to be a valid and reliable instrument to measure health-related quality of life in IBD patients, although our data indicate that the questionnaire is based on a different factor structure from the original IBDQ. There exists a factor structure with four dimensions that are reasonably related to the quality of life in IBD patients. Thus, this instrument has proved to be useful in the quality of life related aspects

evaluation for clinical trials, as well as for the therapeutic management of patients with CD and UC.

#### ACKNOWLEDGEMENTS

This work is supported by Ministerio de Ciencia y Tecnología Grant SAF2002-02211, and grant C03/02 from the Instituto de Salud Carlos III. M. Sans is supported by a grant from Fundación Ramón Areces. M.J. Portella is supported by a postdoctoral contract Juan de la Cierva, from the Ministerio de Educación y Ciencia.

#### REFERENCES

- Vidal A, Gómez E, Panés J. Abordaje psicológico y psiquiátrico de la enfermedad inflamatoria intestinal. *GH Continuada*. 2005;3:122-9.
- Drossman DA, Patrick DL, Mitchell CM, Zagami EA, Appellaum MI. Health-related quality of life in inflammatory bowel disease: functional status and patient worries and concerns. *Dig Dis Sci*. 1989;34:1379-86.
- Guyatt G, Mitchell A, Irvine EJ, Singer J, Williams N, Goodacre R, et al. A new measure of health status for clinical trials in inflammatory bowel disease. *Gastroenterology*. 1989;96:622-9.
- Bergner M, Bobbitt RA. The sickness impact profile: development and final revision of a health status measure. *Med Care*. 1981;19:787-805.
- Dupuy HJ. The Psychological General Well-Being (PGWB) Index. In: Wenger NK, Mattson ME, Furberg CF, Elinson J, editors. Assessment of quality of life in clinical trials of cardiovascular therapies. New York: Le Jacq Publishing; 1984. p. 170-83.
- Russell MG, Pastoor CJ, Brandon S, Rijken J, Engels LG, Van der Heijde DM, et al. Validation of the Dutch translation of the Inflammatory Bowel Disease Questionnaire (IBDQ): a health-related quality of life questionnaire in inflammatory bowel disease. *Digestion*. 1997;58:282-8.
- Cheung WY, Garratt AM, Russell IT, Williams JG. The UK IBDQ: a British version of the Inflammatory Bowel Disease Questionnaire on ulcerative colitis and Crohn's disease. *Digestion*. 1999;60:274-80.
- Kim WH, Cho YS, Yoo HM, Park IS, Park EC, Lim JG. Quality of life in Korean patients with inflammatory bowel diseases: ulcerative colitis, Crohn's disease and intestinal Behçet's disease. *Int J Colorec Dis*. 1999;14:52-7.
- Hjortswang H, Järnerot G, Curman B, Sanberg-Gertzén H, Tysk C, Blomberg B, et al. Validation of the Inflammatory bowel disease questionnaire in Swedish patients with ulcerative colitis. *Scand J Gastroenterol*. 2001;1:77-85.
- Pallis AG, Vlachonikolis IG, Mouzas IA. Quality of life of Greek patients with inflammatory bowel disease. *Digestion*. 2001; 63:240-6.
- Bernklev T, Moum B, Moum T. Quality of life in patients with inflammatory bowel disease: translation, data quality, scaling assumptions, validity, reliability and sensitivity to chance of the Norwegian version of IBDQ. *Scand J Gastroenterol*. 2002;10: 1164-74.
- Leong RWL, Lee YT, Ching JYL, Sung JY. Quality of life in Chinese patients with inflammatory bowel disease: validation of the Chinese translation of the Inflammatory Bowel Disease Questionnaire. *Aliment Pharmacol Ther*. 2003;17:711-8.
- Hauser W, Dietz N, Grand D, Steder-Neukamm U, Janke KH, Stein U, et al. Validation of the Inflammatory Bowel Disease Questionnaire IBDQ-G, German version, for patients with ileal pouch anal anastomosis for ulcerative colitis. *Z Gastroenterol*. 2004;42:131-9.
- Pontes RM, Miszputen SJ, Ferreira-Filho OF, Miranda C, Ferraz MB. Qualidade de vida em pacientes portadores de doença inflamatória intestinal: tradução para o português e validação do questionário Inflammatory Bowel Disease Questionnaire (IBDQ). *Arq Gastroenterol*. 2004;2:137-43.
- Watanabe K, Funayama Y, Fukushima K, Shibata C, Takahashi K, Ogawa H, et al. Assessment of the Japanese Inflammatory

- Bowel Disease Questionnaire in patients after ileal pouch anal anastomosis for ulcerative colitis. *J Gastroenterol.* 2006;41:662-7.
16. López-Vivancos J, Casellas F, Badia X, Vilaseca J, Malagelada JR. Validation of the Spanish version of the inflammatory bowel disease questionnaire on ulcerative colitis and Crohn's disease. *Digestion.* 1999;60:274-80.
  17. Love JR, Irvine EJ, Fedorak RN. Quality of life in inflammatory bowel disease. *J Clin Gastroenterol.* 1992;14:15-9.
  18. Lennard-Jones JE. Classification of Inflammatory Bowel Disease. *Scand J Gastroenterol.* 1989;24:2-6.
  19. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. *Acta Psychiatr Scand.* 1983;67:361-70.
  20. Herrero MJ, Blanch J, Peri JM, De Pablo J, Pintor L, Bulbena A. A validation study of the Hospital Anxiety and Depression Scale (HADS) in a Spanish population. *Gen Hosp Psychiatry.* 2003;25:277-83.
  21. Cloninger CR. A systematic method for clinical description and classification of personality variants. *Arch Gen Psychiatry.* 1987;44:573-88.
  22. Gutiérrez F, Torrens M, Boget T, Martín-Santos R, Sangorrín J, Pérez G, et al. Psychometric properties of the Temperament and Character Inventory (TCI) questionnaire in a Spanish psychiatric population. *Acta Psychiatr Scand.* 2001;103:143-7.
  23. Van Hees PA, Van Elteren PH, Van Lier HJ. An index of inflammatory activity in patients with Crohn's disease. *Gut.* 1980;21:289-96.
  24. Truelove SC, Witts LJ. Cortisone in ulcerative colitis: Final report on a therapeutic trial. *BMJ.* 1955;2:1041-9.
  25. R: Copyright 2005. The R Foundation for Statistical Computation Version 2.2.1 (ISBN 3-900051-07-0).
  26. Hu L, Bentler PM. Cutoff criteria for the indexes in covariance structure analysis: conventional criteria versus new alternatives. *Structural Equation Modelling.* 1999;6:1-55.